Moses named chair of Grey Wolf; Zong joining Harbour BioMed
Remembering a trio of European pioneers
Grey Wolf Therapeutics Ltd. has appointed serial entrepreneur Edwin Moses as chair. Over a career spanning more than three decades, Moses led Oxford Asymmetry International plc and Ablynx NV to acquisitions, and served as chair of Dark Blue Therapeutics Ltd., a U.K. biotech acquired by Amgen Inc. (NASDAQ:AMGN). He is currently chair of Avantium Technologies B.V., the Sofinnova Partners-backed green biotech, as well as LabGenius Ltd. and Nanosyrinx Ltd. U.K.-based Grey Wolf has raised more than $110 million in venture funding and is developing antigen modulation therapies for cancer, autoimmune disorders and infectious diseases.
Cross-border biotech HBM Holdings Ltd. (HKEX:02142), known informally as Harbour BioMed, hired Adam Zong as president. Zong was founding CEO of Hengrui Therapeutics U.S., where he helped lead the China company’s global expansion...